SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BJCT-BIOJECT-needle less injection product
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: geewiz who wrote (29)8/12/1997 10:53:00 PM
From: novice investor   of 534
 
Hi Art,

Thanks for the detailed e-mail.

I'm very curious about the BJCT's marketing plan. Do they have one? I'm afraid I have no expertise to determine if BJCT has viable technology and am forced to make empirical judgement based purely on market reception of BJCT products; it concerns me greatly to see no aggressive marketing actions for the entire time I've held their stock.

I've always considered the Biojector to be a high-tech version of the needle and syringe; in fact, from a strictly clinical point of view, anything a Biojector can do can also be done with a needle and syringe. Am I correct in this assumption? This means that the true selling point of Biojector is based mainly on its comfort level for the patients and this product becomes attractive only if the cost differential for its use is low enough for the clinics to actually consider patients' comfort. Since needle replacements cost pennies, generic use of Biojectors may be a tough sell.

Hope I'm wrong on my perception.

NI
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News